Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management

Purpose of Review This article presents a comprehensive review of the spectrum of treatments utilized for Lennox-Gastaut Syndrome (LGS) in children and adults, including pharmacologic, surgical, neuromodulatory and diet therapies. This review also discusses considerations of common comorbidities associated with LGS, as well as clinical trials exploring emerging new therapies. Recent Findings The therapeutic landscape of LGS is growing. There are currently 8 FDA approved anti-seizure medications (ASMs) indicated for the treatment of LGS, and several others are widely used off label. Several recent expert opinion consensus algorithms have been reported to guide the use of pharmacologic options. Additionally, neuromodulatory as well as diet therapies have been found to control seizures and in appropriately selected patients surgical options including disconnections such as corpus callosotomy procedures may be beneficial. Summary Lennox-Gastaut Syndrome (LGS) is a complex developmental and epileptic encephalopathy characterized by drug-resistant seizures, neurocognitive impairment, and distinct electrographic hallmarks. Given its refractory nature, treatment requires a structured, multimodal strategy that balances aggressive seizure reduction with comorbidity management. This involves appropriate trials with carefully chosen anti-seizure medications, and early evaluations for non-pharmacologic and surgical options especially when refractory. As patients transition into adulthood, management must adapt. Seizure patterns and electrographic features often evolve, requiring therapy individualized for seizure types such as sodium channel blockers for focal onset seizures. Furthermore, optimal care must extend beyond seizure frequency to address critical non-seizure comorbidities, including sleep disruption, psychiatric symptoms, and behavioral dysregulation. Finally, as genetic testing continues to uncover underlying etiologies, integrating emerging precision therapies targeting specific molecular pathways will be paramount to modifying the long-term neurodevelopmental trajectory of LGS.

Authors

Institutions

Publication Details

Journal
Current Treatment Options in Neurology
Published
2026-11-20
DOI
https://doi.org/10.1007/s11940-026-00898-2
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management

Aditi M. Trivedi, Rajdeep Singh, Isabella Mateo, Ruhee Patel
Current Treatment Options in Neurology
Epilepsy research and treatment
article

Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management

Aditi M. Trivedi, Rajdeep Singh, Isabella Mateo, Ruhee Patel
article en

Abstract

Purpose of Review This article presents a comprehensive review of the spectrum of treatments utilized for Lennox-Gastaut Syndrome (LGS) in children and adults, including pharmacologic, surgical, neuromodulatory and diet therapies. This review also discusses considerations of common comorbidities associated with LGS, as well as clinical trials exploring emerging new therapies. Recent Findings The therapeutic landscape of LGS is growing. There are currently 8 FDA approved anti-seizure medications (ASMs) indicated for the treatment of LGS, and several others are widely used off label. Several recent expert opinion consensus algorithms have been reported to guide the use of pharmacologic options. Additionally, neuromodulatory as well as diet therapies have been found to control seizures and in appropriately selected patients surgical options including disconnections such as corpus callosotomy procedures may be beneficial. Summary Lennox-Gastaut Syndrome (LGS) is a complex developmental and epileptic encephalopathy characterized by drug-resistant seizures, neurocognitive impairment, and distinct electrographic hallmarks. Given its refractory nature, treatment requires a structured, multimodal strategy that balances aggressive seizure reduction with comorbidity management. This involves appropriate trials with carefully chosen anti-seizure medications, and early evaluations for non-pharmacologic and surgical options especially when refractory. As patients transition into adulthood, management must adapt. Seizure patterns and electrographic features often evolve, requiring therapy individualized for seizure types such as sodium channel blockers for focal onset seizures. Furthermore, optimal care must extend beyond seizure frequency to address critical non-seizure comorbidities, including sleep disruption, psychiatric symptoms, and behavioral dysregulation. Finally, as genetic testing continues to uncover underlying etiologies, integrating emerging precision therapies targeting specific molecular pathways will be paramount to modifying the long-term neurodevelopmental trajectory of LGS.

Current Treatment Options in NeurologyVol. 28(1)
University of California San Diego (US), Wake Forest University (US)
Wake Forest University
Good health and well-being
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon